AI assistant
KALA BIO, Inc. — Director's Dealing 2025
Jun 6, 2025
35091_dirs_2025-06-05_326baf4d-1db1-40e7-a8a4-b175c16e8937.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: KALA BIO, Inc. (KALA)
CIK: 0001479419
Period of Report: 2025-06-03
Reporting Person: Iwicki Mark T (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-03 | Common Stock | S | 10866 | $3.74 | Disposed | 269210 | Direct |
Footnotes
F1: This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023.
F2: This amendment is being filed solely to correct the nature of the transaction reported in Column 4 of Table I of the Form 4 filed by the Reporting Person on June 4, 2025. As reported in this amendment, such transaction resulted in a "disposition" of common stock by the Reporting Person and not an "acquisition" as previously reported.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F4: Includes 154,042 unvested RSUs.